

Wang X, Haylock D, Hu CS, et al. A thrombopoietin receptor antagonist is capable of depleting myelofibrosis hematopoietic stem and progenitor cells. *Blood*. 2016;127(26):3398-3409.

On page 3398 of the 30 June 2016 issue, one of the affiliations of author David Winkler is incomplete. Affiliation 5 should read, “La Trobe Institute for Molecular Science, La Trobe University, Melbourne, VIC, Australia.” The error has been corrected in the online version, which now differs from the print version.

DOI 10.1182/blood-2017-11-815340

© 2017 by The American Society of Hematology

Li H, Choesang T, Bao W, et al. Decreasing TfR1 expression reverses anemia and hepcidin suppression in β -thalassemic mice. *Blood*. 2017;129(11):1514-1526.


In “Acknowledgments” on page 1524 in the 16 March 2017 issue, support from the European Research Council Starting Grant 261178 for Antonia Follenzi is missing. The error has been corrected in the online version, which now differs from the print version.

DOI 10.1182/blood-2017-11-815167

© 2017 by The American Society of Hematology

Konkle BA. Impacting inhibitor development in hemophilia A. *Blood*. 2017;130(15):1689-1690.

In the figure on page 1689 in the 12 October 2017 issue, “% with inhibitor” should read “% without inhibitor” in both panels. The corrected figure is shown below. The errors have been corrected in the online version, which now differs from the print version.



Kaplan-Meier curves show the cumulative incidence of being without an inhibitor by treatment type in patients with *F8* DNA variants that put them at low risk (A) or high risk (B) of developing a factor VIII inhibitor. This figure has been adapted from Figure 1 in the article by Rosendaal et al that begins on page 1757.

DOI 10.1182/blood-2017-11-815100

© 2017 by The American Society of Hematology